Author

E. R. McGlone

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 4 Approach:experimental assay· 4 Organism:human· 3 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Tomas· 5 shared B. Jones· 5 shared S. R. Bloom· 5 shared T. M. Tan· 4 shared A. Inoue· 3 shared I. R. Correa· 3 shared P. Pickford· 3 shared D. Carling· 2 shared

Activity by Year

2018-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersPharmacology & Toxicology

A. Tomas

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Hepatocyte cholesterol content modulates glucagon receptor signalling

E. R. McGlone, T. B. Ansell, C. Dunsterville, W. Song, D. Carling, A. Tomas, S. R. Bloom, M. Sansom, T. M. Tan, B. Jones

This study shows that hepatocyte cholesterol content affects glucagon receptor signaling, with higher cholesterol reducing glucagon's ability to lower blood sugar in NAFLD.

bioRxiv · Oct 31, 2021Pharmacology & Toxicology

Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling

E. R. McGlone, Y. Manchanda, B. Jones, P. Pickford, A. Inoue, D. Carling, S. R. Bloom, T. M. Tan, A. Tomas

This study investigates how RAMP2 affects GCGR trafficking and signaling in hepatocytes, showing it alters receptor internalization and signaling bias with limited metabolic impact.

bioRxiv · May 9, 2021Cell Biology

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist

P. Pickford, M. Lucey, R.-M. Rujan, E. R. McGlone, S. Bitsi, F. Ashford, I. R. Correa, D. Hodson, A. Tomas, G. Deganutti, C. A. Reynolds, B. M. Owen, T. M. Tan, J. Minnion, S. R. Bloom, B. Jones

This study shows that partial agonism of GLP-1R/GCGR co-agonists improves anti-hyperglycaemic efficacy by reducing β-arrestin-2 recruitment, leading to prolonged glucose-lowering effects and comparable weight loss to liraglutide.

bioRxiv · Mar 2, 2021Pharmacology & Toxicology

Signal bias at glucagon family receptors: rationale and downstream impacts

B. Jones, E. R. McGlone, Z. Fang, P. Pickford, I. R. Correa, A. Oishi, R. Jockers, A. Inoue, S. Kumar, F. Görlitz, C. Dunsby, P. M. French, G. A. Rutter, T. M. Tan, A. Tomas, S. R. Bloom

The paper investigates signal bias at glucagon family receptors, showing biased agonists affect intracellular signaling and insulin secretion differently.

bioRxiv · Apr 26, 2020Pharmacology & Toxicology

Agonist binding affinity determines palmitoylation of the glucagon-like peptide-1 receptor and its functional interaction with plasma membrane nanodomains in pancreatic beta cells

T. Buenaventura, W. E. Laughlin, S. Bitsi, T. Burgoyne, Z. Lyu, A. I. Oqua, H. Norman, E. R. McGlone, A. S. Klymchenko, I. R. Correa, A. Walker, A. Inoue, A. Hanyaloglou, G. A. Rutter, S. R. Bloom, , A. Tomas

This study shows that agonist binding affinity affects GLP-1R palmitoylation, nanodomain clustering, and signaling in pancreatic beta cells, influencing insulin secretion.

bioRxiv · Dec 10, 2018Cell Biology